SAGE Therapeutics (SAGE) Reports Q2 Loss of $0.36
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Stifel Transfers Sage Therapeutics (SAGE), Maintains Buy
August 6, 2018 4:16 PM EDTStifel assumes coverage on Sage Therapeutics (NASDAQ: SAGE) with a Buy rating and a price target of $239.00.
Analyst Paul Matteis assumes coverage, maintains Buy and raises the PT to $239.00 (from $198.00)
For an analyst ratings summary and ratings history on Sage Therapeutics... More
Piper Jaffray Starts Sage Therapeutics (SAGE ) at Overweight
August 6, 2018 5:34 AM EDTPiper Jaffray initiates coverage on Sage Therapeutics (NASDAQ: SAGE ) with a Overweight rating and a price target of $206.00.
Analyst Danielle Brill believes the company is attractive citing robust supportive data generated in 2018, the novel approach to threat of CNS disorders, the pipeline depth, and consistent management... More
